VANC Pharmaceuticals falls from high as Venture slump deepens

For a moment on Thursday morning it looked like VANC Pharmaceuticals (NPH:TSXV) was never going to come back down.

Junior healthcare stock: VANC Pharmaceuticals fails to hold gains

The Vancouver-based junior healthcare stock hit a high of $0.94 per share Thursday as more than 9.1 million shares traded. Selling then sharply began to outweigh buying in the deal as its shares fell to a low of $0.65 Thursday, before closing at $0.68.

The selloff continued Friday as VANC hit a low of $0.51 before rebounding to $0.60 at 1:47 PM EDT. Its shares were still down 11.7% on the day. VANC was not the only stock in decline as the TSX Venture gave up over 1.6% of its value.

VANC is a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets.

VANC Pharmaceuticals provided a brief corporate update on March 12th, where it announced having reaped $2 million in proceeds from warrant exercises.

Arun Nayyar, CEO of Vanc, commented that,

“This injection of capital will assist us in two key areas of our Company as it puts us in a position to ramp up our Sales and Marketing team and allows for additional product acquisitions.”

And that,

“We expect to begin shipping in Q2-2015 and have spent considerable time reviewing several product acquisitions that fit into our existing portfolio of generics and OTC products.”

Below is a short excerpt from the press release.

“The Company expects initial inventory for 30 generic molecules to be delivered in early Q2-2015 and will commence manufacturing on the OTC products in Q2-2015 as well.”

Click here to read the entire press release.

Liquidity in Vanc Pharmaceuticals remains high as retail investors buy and sell

Retail investors have been attracted to Vanc Pharmaceuticals for two specific reasons: the company is entering a growing market, drugs, and more specifically, generic drugs; and, secondly, due to the potential revenue associated with the British Columbia (BC) Ministry of Health approval of 14 of the Company’s generic molecules.

The recent approval from the BC Ministry of Health, making them eligible for listing on British Columbia’s provincial formulary and for reimbursement through Pharmacare, has investors very curious about revenue potential.

Manufacturing of the OTC products scheduled for Q2-2015, according to the most recent quote from Vanc`s CEO and President highlighted above.

Our most recent article on the company is from March 11th, titled Vanc Pharmaceuticals explodes to new 52-week high. Below is  a short excerpt.

“Vanc Pharmaceuticals’ stock continue historic rally

Vanc Pharmaceuticals’ stock traded some 5.8 million shares Wednesday, its 4th most liquid trading day in the past 30 trading days.

The volume propelled Vanc to a new all-time high of $0.76 per share, before settling at $0.74 – up 32.14% on the day.

Everything began to change for Vanc Pharmaceuticals following its Feburary 24th press release, when the company announced that it has received confirmation from the British Columbia (BC) Ministry of Health approving 14 of the Company’s generic molecules under the Low Cost Alternative (LCA) program.

The company reported that, “The approval of these molecules makes them eligible for listing on British Columbia’s provincial formulary and for reimbursement through Pharmacare.”

Click here to read the entire press release.”

Investors will likely have to wait until Q3 or Q4 of 2015 to get a better understanding of any potential revenue for Vanc Pharmaceuticals and their planned rollout of the Company’s approved generic molecules.

This article represents solely the opinions of Alexander Smith. Alexander Smith is not an investment advisor and any reference to specific securities in the list referred to in the article does not constitute a recommendation thereof. Readers are encouraged to consult their investment advisors prior to making any investment decisions. The information in this article is of an impersonal nature and should not be construed as individualized advice or investment recommendations.

This is not an invitation to purchase any securities mentioned in this report. Pinnacle Digest does not endorse or recommend any of the referenced securities. At the time of publication and distribution of this report (12:30PM PST on March 13, 2015) neither PinnacleDigest.com, its employees or consultants owned shares in any of the mentioned companies in this report. This article is intended for informational and entertainment purposes only. The author of this article bears no liability for losses and/or damages arising from the use of this article. This report may contain technical or other inaccuracies, omissions, or typographical errors, for which PinnacleDigest.com and its parent company assumes no responsibility. We do not guarantee that any of the companies mentioned in this report or on PinnacleDigest.com will perform as we expect, and any comparisons we have made to other companies may not be valid or come into effect.

All statements in this report, other than statements of historical fact, should be considered forward-looking statements. These statements relate to future events or future performance. Much of this report is comprised of statements of projection. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements.

PinnacleDigest.com and its employees are not a registered broker-dealer or financial advisors. Before investing in any securities, you should consult with your financial advisor and a registered broker-dealer. Nothing in this article should be construed as a solicitation to buy or sell any securities. This article is intended for informational and entertainment purposes only. The author of this article bears no liability for losses and/or damages arising from the use of this article.